Compare ADMA & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADMA | GTLB |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 2012 | 2021 |
| Metric | ADMA | GTLB |
|---|---|---|
| Price | $13.80 | $22.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 28 |
| Target Price | $32.00 | ★ $40.96 |
| AVG Volume (30 Days) | 3.6M | ★ 6.4M |
| Earning Date | 05-06-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | $42,219,783.00 | ★ $955,224,000.00 |
| Revenue This Year | $27.46 | $20.08 |
| Revenue Next Year | $22.11 | $18.83 |
| P/E Ratio | $24.02 | ★ N/A |
| Revenue Growth | ★ 43.85 | 25.81 |
| 52 Week Low | $13.76 | $21.98 |
| 52 Week High | $25.67 | $53.55 |
| Indicator | ADMA | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 33.35 | 31.18 |
| Support Level | N/A | N/A |
| Resistance Level | $16.87 | $50.50 |
| Average True Range (ATR) | 0.73 | 0.96 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 0.62 | 13.71 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.